Market revenue in 2023 | USD 41.9 million |
Market revenue in 2030 | USD 71.3 million |
Growth rate | 7.9% (CAGR from 2023 to 2030) |
Largest segment | Contract manufacturing |
Fastest growing segment | Contract Development |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Contract Manufacturing, Contract Development |
Key market players worldwide | Eurofins Scientific SE, WuXi Biologics (Cayman) Inc, Catalent Inc, AGC Inc, Siegfried Holding AG, Boehringer Ingelheim, FUJIFILM Holdings Corp, Samsung BioLogics, Rentschler Biopharma SE, Recipharm |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to large molecule drug substance cdmo market will help companies and investors design strategic landscapes.
Contract manufacturing was the largest segment with a revenue share of 67.06% in 2023. Horizon Databook has segmented the Saudi Arabia large molecule drug substance cdmo market based on contract manufacturing, contract development covering the revenue growth of each sub-segment from 2018 to 2030.
The Clinical Trials Administration is formed to provide services professionally by evaluation, registration, and monitoring of trials conducted in Saudi Arabia, which helps protect clinical trial subjects as well as improve experience of investigators in the field of clinical research, while strengthening the capacity of regulatory body and legislative & oversight functions.
Since February 2000, 405 trials have been registered in Saudi Arabia. These trials fall into one of the 22 different ICD-10 codes, and with the top four being neoplasms (92); diseases of the circulatory system (57); endocrine, nutritional & metabolic diseases (46); and diseases of the respiratory system (25).
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia large molecule drug substance cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia large molecule drug substance cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account